JP2019529581A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529581A5
JP2019529581A5 JP2019540308A JP2019540308A JP2019529581A5 JP 2019529581 A5 JP2019529581 A5 JP 2019529581A5 JP 2019540308 A JP2019540308 A JP 2019540308A JP 2019540308 A JP2019540308 A JP 2019540308A JP 2019529581 A5 JP2019529581 A5 JP 2019529581A5
Authority
JP
Japan
Prior art keywords
composition
gain
patient
missense mutation
function missense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019540308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529581A (ja
JP6892151B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/055970 external-priority patent/WO2018093484A1/en
Publication of JP2019529581A publication Critical patent/JP2019529581A/ja
Publication of JP2019529581A5 publication Critical patent/JP2019529581A5/ja
Application granted granted Critical
Publication of JP6892151B2 publication Critical patent/JP6892151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019540308A 2016-10-11 2017-10-10 Ｅｒ＋乳がんのラソフォキシフェン処置 Active JP6892151B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662406859P 2016-10-11 2016-10-11
US62/406,859 2016-10-11
US201762457759P 2017-02-10 2017-02-10
US62/457,759 2017-02-10
US201762502299P 2017-05-05 2017-05-05
US62/502,299 2017-05-05
PCT/US2017/055970 WO2018093484A1 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021022514A Division JP7247241B2 (ja) 2016-10-11 2021-02-16 Ｅｒ＋乳がんのラソフォキシフェン処置

Publications (3)

Publication Number Publication Date
JP2019529581A JP2019529581A (ja) 2019-10-17
JP2019529581A5 true JP2019529581A5 (https=) 2020-11-19
JP6892151B2 JP6892151B2 (ja) 2021-06-23

Family

ID=60186386

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019540308A Active JP6892151B2 (ja) 2016-10-11 2017-10-10 Ｅｒ＋乳がんのラソフォキシフェン処置
JP2021022514A Active JP7247241B2 (ja) 2016-10-11 2021-02-16 Ｅｒ＋乳がんのラソフォキシフェン処置
JP2023003699A Active JP7418052B2 (ja) 2016-10-11 2023-01-13 Ｅｒ＋乳がんのラソフォキシフェン処置
JP2023219161A Active JP7774896B2 (ja) 2016-10-11 2023-12-26 Ｅｒ＋乳がんのラソフォキシフェン処置

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021022514A Active JP7247241B2 (ja) 2016-10-11 2021-02-16 Ｅｒ＋乳がんのラソフォキシフェン処置
JP2023003699A Active JP7418052B2 (ja) 2016-10-11 2023-01-13 Ｅｒ＋乳がんのラソフォキシフェン処置
JP2023219161A Active JP7774896B2 (ja) 2016-10-11 2023-12-26 Ｅｒ＋乳がんのラソフォキシフェン処置

Country Status (20)

Country Link
US (8) US20180098963A1 (https=)
EP (2) EP3525774B1 (https=)
JP (4) JP6892151B2 (https=)
KR (5) KR102285453B1 (https=)
CN (3) CN112933082A (https=)
AU (3) AU2017360365B2 (https=)
BR (1) BR112019007254A2 (https=)
CA (1) CA3040266A1 (https=)
DK (1) DK3525774T3 (https=)
ES (1) ES2909576T3 (https=)
IL (2) IL284875B (https=)
MX (2) MX387856B (https=)
NZ (1) NZ752443A (https=)
PL (1) PL3525774T3 (https=)
PT (1) PT3525774T (https=)
RU (1) RU2019114079A (https=)
SG (2) SG10201913951YA (https=)
TW (4) TWI836808B (https=)
WO (2) WO2018071440A1 (https=)
ZA (1) ZA201902454B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US20180098963A1 (en) 2016-10-11 2018-04-12 Duke University Lasofoxifene treatment of breast cancer
CN117771239A (zh) * 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN119947719A (zh) * 2022-05-25 2025-05-06 瑟默尼克斯制药公司 拉索昔芬联合治疗cdk4/6抑制剂治疗后进展的er+乳腺癌
WO2025075631A1 (en) 2023-10-06 2025-04-10 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of endocrine therapy resistant er+ cancer
MX2023013107A (es) * 2023-11-06 2025-06-02 Centro De Investig Y De Estudios Avanzados Del I P N Composiciones sinergicas de loratadina-raloxifeno-sorafenib para el tratamiento de cancer hepatico.
WO2025122504A1 (en) * 2023-12-04 2025-06-12 Foundation Medicine, Inc. Esr1 mutations, esr1 co-occurring mutations, and uses thereof
WO2025165887A1 (en) * 2024-01-30 2025-08-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations
CN119842900A (zh) * 2025-01-17 2025-04-18 厦门飞朔生物技术有限公司 一种可用于乳腺癌内分泌耐药治疗指导的人esr1基因突变检测试剂盒

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6277834B1 (en) 1998-06-19 2001-08-21 Senju Pharmaceutical Co. Ltd. Agents for relieving side effects of adrenal cortex hormone
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CN1400904A (zh) 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
AU2002235348A1 (en) 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
RS80604A (sr) 2002-03-28 2007-02-05 Pfizer Products Inc., Prečišćen lazofoksifen i postupci prečišćavanja lazofoksifena rekristalizacijom
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20110015134A1 (en) 2007-04-16 2011-01-20 Retsky Michael W Method of treatment for early stage cancer
CZ2007373A3 (cs) 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
WO2009137543A2 (en) * 2008-05-06 2009-11-12 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
US20110288142A1 (en) 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
EP2239570A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the estrogen receptor status of breast cancer
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
WO2012024255A2 (en) 2010-08-16 2012-02-23 Duke University Camkk-beta as a target for treating cancer
US20120052508A1 (en) * 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
WO2012158657A1 (en) 2011-05-18 2012-11-22 Merck Sharp & Dohme Corp. Therapeutic anti-igf1r combinations
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9204286B1 (en) 2013-03-15 2015-12-01 Sprint Communications Company L.P. System and method of branding and labeling a mobile device
CA2941161A1 (en) * 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
AU2015341700A1 (en) 2014-11-07 2017-06-08 Lipoxen Technologies Limited Method for treatment of primary hormone resistant endometrial and breast cancers
US20180049999A1 (en) 2015-04-14 2018-02-22 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
WO2018071437A1 (en) 2016-10-11 2018-04-19 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
US20180098963A1 (en) 2016-10-11 2018-04-12 Duke University Lasofoxifene treatment of breast cancer
WO2018129645A1 (en) 2017-01-10 2018-07-19 Wang, Wei Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
CA3109090A1 (en) * 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
JP2024538689A (ja) 2021-10-05 2024-10-23 デューク ユニバーシティ 腫瘍免疫の小分子制御因子を含む組成物及びその使用方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN119947719A (zh) 2022-05-25 2025-05-06 瑟默尼克斯制药公司 拉索昔芬联合治疗cdk4/6抑制剂治疗后进展的er+乳腺癌

Similar Documents

Publication Publication Date Title
JP2019529581A5 (https=)
CN108024541B (zh) 用于治疗癌症的方法
RU2019114079A (ru) Лечение er+ рака молочной железы лазофоксифеном
JP2019518765A5 (https=)
IL292659A (en) Methods for treating breast cancer ar plus
WO2015082990A1 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
US20230330106A1 (en) Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant
RU2016148441A (ru) Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом
JP2019508476A5 (https=)
US20240173306A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
JP7376540B2 (ja) リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体２陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ
JP2026016396A (ja) 乳がんの治療のための併用療法
CN107249587B (zh) 用于治疗乳腺癌的抗组胺药
EP3654967A1 (en) Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
EP3919058A1 (en) Use of composition containing cdk4/6 inhibitor in combination with anastrozole in preparation of medicament for treating tumor diseases
US20230381156A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib
JPWO2023091553A5 (https=)
JPH09506902A (ja) 前立線癌の化学療法剤の補助剤
JP7846700B2 (ja) Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌
JPWO2021214253A5 (https=)
HK40101825A (zh) 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌
JP2023086719A (ja) Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂